Dr.GENG Meiyu  is a professor and principle investigator of Shanghai Institute of Materia Medica. She also serves as the secretary of the party committee and deputy director of the institute. Dr. Geng is a receipt of “National Science Foundation for Distinguished Young Scholars” and "Hundred Talents Program” of Chinese Academy of Sciences. Geng’s research has focused on the development of molecularly targeted therapies for cancer and Alzheimer's disease treatment. She has played a leading role in the development of four novel drug candidates. An oligosaccharide that targets β-amyloid protein for Alzheimer disease treatment is undergoing phase III clinical trial. The other three tyrosine kinase inhibitors targeting c-Met, ALK or FGFR respectively are in preclinical studies.